SARS-CoV-2 mRNA疫苗(SYS6006)在健康中国参与者中的免疫原性和安全性:一项随机、观察者盲法、安慰剂对照的2期临床试验
该随机、观察者盲法、安慰剂对照2期试验纳入免疫学初免的300名成人和150名老年人,按1:1:1随机接受20µg或30µg SYS6006或安慰剂两剂接种。结果显示SYS6006安全性良好,未报告疫苗相关严重不良事件,并诱导了稳健的野生型中和抗体和S1-IgG反应,对Omicron BA.5的中和抗体反应较弱。
要点
- SYS6006两剂接种在18岁及以上免疫学初免健康参与者中安全性、耐受性和免疫原性良好。
- 第二剂后14天(第35天),20µg和30µg组成人野生型中和抗体几何平均滴度分别为91.3和84.9,老年组分别为74.0和115.9。
- 最常见不良事件为注射部位疼痛和发热,多数为1级或2级,未报告疫苗相关严重不良事件。
核心结论
- 两剂SYS6006接种在18岁及以上免疫学初免健康参与者中表现出良好的安全性、耐受性和免疫原性。
研究设计与样本
- 观察者盲法、随机、安慰剂对照2期临床试验,纳入免疫学初免的300名成人和150名老年人,按1:1:1随机接受两剂20µg或30µg SYS6006或安慰剂。
- 不良事件记录至第二剂后30天,检测活病毒中和抗体、S1蛋白特异性结合抗体和细胞免疫。
主要发现
- 第二剂后14天(第35天),20µg和30µg组成人野生型中和抗体几何平均滴度分别为91.3和84.9,老年组分别为74.0和115.9。
- 除两名参与者外,所有参与者野生型中和抗体均发生血清阳转。
- 对Omicron BA.5的中和抗体反应较弱。
- 第35天,20µg和30µg组成人野生型S1-IgG几何平均浓度分别为2751.0和3142.2 BAU/mL,老年组分别为2474.1和2993.5 BAU/mL。
- 诱导了对Omicron BA.2的S1-IgG反应,并激发了细胞免疫,尤其在酶联免疫斑点试验中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine enables quick upgrade of antigen sequence to combat emerging new variants. In an observer-blinded, randomized, placebo-controlled phase 2 trial, immunologically naïve 300 adults and 150 older participants were enrolled and randomized (1:1:1) to receive two doses of 20 µg or 30 µg of a SARS-CoV-2 mRNA vaccine (SYS6006) or placebo. Adverse events (AEs) were recorded through 30 days after the second dose. Live virus neutralizing antibody (Nab), S1 protein-specific binding antibody (S1-IgG) and cellular immunity were tested. Results showed that robust wild-type Nab response was elicited with geometric mean titers of 91.3 and 84.9 in the adults, and 74.0 and 115.9 in the elders, 14 days following the second dose (Day 35) in the 20-µg and 30-µg groups, respectively. All seroconverted for wild-type Nab except two participants. Nab against Omicron BA.5 was mild. Robust wild-type S1-IgG response was induced with geometric mean concentrations of 2751.0 and 3142.2 BAU/mL in adults, and 2474.1 and 2993.5 BAU/mL in elders at Day 35 in the 20-µg and 30-µg groups, respectively. S1-IgG against Omicron BA.2 was induced. Cellular immunity was elicited, particularly in enzyme-linked immunospot assay. The most frequent AEs were injection-site pain and fever. Most reported AEs were grade 1 or grade 2. The AE incidences were similar following the first dose and second dose. No vaccination-associated serious AE was reported. In conclusion, two-dose vaccination with SYS6006 demonstrated good safety, tolerability and immunogenicity in immunologically naïve healthy participants aged 18 years or more.
引用
- Jin F, Qiu Y, Wu Z, et al. Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial. Vaccine. 2024. PMID: 38365485. doi:10.1016/j.vaccine.2024.01.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。